ProBioGen in Biosimilar Deal with Bio Farma Indonesia
Complete the form below to unlock access to ALL audio articles.
ProBioGen AG and Bio Farma have signed an agreement for the development of a biosimilar Trastuzumab for cancer treatment. The goal of the co-operation is the supply of the Indonesian patients with cost-effective high quality biopharmaceuticals.
Under the terms of the agreement ProBioGen will develop a highly efficient manufacturing process based on a specifically designed recombinant CHO-cell line, conduct engineering runs and the industrial scale-up.
The turn-key process, including analytics, will then be transferred to Indonesia to enable local market production. The agreement is fee-for-service based, license and royalty-free.
Dr. Wieland Wolf, ProBioGen’s CEO commented: “This is the 1st Trastuzumab molecule which will be produced locally for the Indonesian market to provide effective modern medicines for a country of 250 million people. We are proud to be a partner of the well-established and experienced Bio Farma, a government company with a successful history of more than 120 years.”
Dr. Gabriele Schneider, Vice President Business Development of ProBioGen added: “The task to develop high-quality therapeutic proteins with high productivity but low commercial-scale production costs fits very well to our passion for developing intelligent biopharmaceutical solutions, based on our in-house CHO manufacturing platform of adapted cells, robust and economical process development know-how and chemically defined media platform.”
Dr. Iskandar, President Director of Bio Farma stated “Bio Farma is proud to be collaborating with ProBioGen. This collaboration will undoubtedly enhance our vision to enter lifescience industry, where in future it will contribute to producing high-quality biopharmaceuticals particulary for the Indonesian people and others in the world.”
